Post Marketing Surveillance Study For Sayana®

POST MARKETING SURVEILLANCE TO OBSERVE SAFETY AND EFFICACY OF SAYANA(REGISTERED) USED FOR CONTRACEPTION AND MANAGEMENT OF ENDOMETRIOSIS-ASSOCIATED PAIN

Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception And Management Of Endometriosis-Associated Pain

Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who randomly visit the site who meet the inclusion/exclusion criteria.

Inclusion Criteria:

- Subjects or legally authorized representatives of pediatric subjects agree to provide written informed consent form (ie, data privacy statement).

2.Women subjects who are initiating treatment with Sayana® for the first time as per the local product document for usage

Exclusion Criteria:

• Known or suspected pregnancy.
• Undiagnosed vaginal bleeding.
• Known or suspected malignancy of breast.
• Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease.
• Significant liver disease.
• Known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients.
• Women who are before menarche or who are post-menopausal.
• Treatment with any investigational agent or device within 30 days prior to the enrollment visit.